Denali Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Denali Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 25.6% bzw. 63.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 27.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -36.9% betragen.

Wichtige Informationen

25.6%

Wachstumsrate der Gewinne

27.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	63.7%
Zukünftige Eigenkapitalrendite	-36.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 20

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Jul 26

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

May 23

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 13

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Apr 17

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Mar 21

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 07

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Feb 21

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Jan 26

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Nov 20

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Oct 09

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Aug 22

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

May 02

Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Mar 04

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

Feb 06

These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Nov 09

Denali Therapeutics proposes $250M stock offering; shares down 6% post market

Oct 18

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Oct 12

Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

Oct 10

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Jun 08

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:DNLI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	233	-414	-107	-206	11
12/31/2025	70	-486	-505	-274	13
12/31/2024	12	-453	-557	-356	14
9/30/2024	N/A	-427	-376	-363	N/A
6/30/2024	1	-420	-402	-391	N/A
3/31/2024	295	-137	-425	-413	N/A
12/31/2023	331	-145	-371	-358	N/A
9/30/2023	341	-124	-348	-332	N/A
6/30/2023	343	-128	-321	-302	N/A
3/31/2023	101	-371	-248	-231	N/A
12/31/2022	108	-326	-263	-245	N/A
9/30/2022	111	-303	-254	-238	N/A
6/30/2022	112	-284	-234	-222	N/A
3/31/2022	83	-286	-243	-233	N/A
12/31/2021	49	-291	-220	-211	N/A
9/30/2021	353	30	361	368	N/A
6/30/2021	357	56	404	410	N/A
3/31/2021	340	58	415	420	N/A
12/31/2020	336	71	413	416	N/A
9/30/2020	24	-228	-150	-145	N/A
6/30/2020	28	-216	-183	-176	N/A
3/31/2020	26	-215	-193	-176	N/A
12/31/2019	27	-198	-169	-152	N/A
9/30/2019	148	-66	-27	-11	N/A
6/30/2019	135	-55	-30	-15	N/A
3/31/2019	133	-52	-19	-14	N/A
12/31/2018	129	-36	47	50	N/A
9/30/2018	3	-137	-64	-61	N/A
6/30/2018	2	-123	N/A	-49	N/A
3/31/2018	1	-91	N/A	-24	N/A
12/31/2017	N/A	-88	N/A	-77	N/A
9/30/2017	N/A	-85	N/A	-77	N/A
6/30/2017	N/A	-93	N/A	-76	N/A
3/31/2017	N/A	-90	N/A	-75	N/A
12/31/2016	N/A	-87	N/A	-72	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DNLI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: DNLI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: DNLI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: DNLIDie Einnahmen des Unternehmens (63.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: DNLIDie Einnahmen des Unternehmens (63.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DNLI wird voraussichtlich in 3 Jahren unrentabel sein.

Denali Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 49%

Consensus revenue estimates decrease by 14%

Consensus revenue estimates decrease by 45%, EPS upgraded

Consensus revenue estimates fall by 29%

Consensus revenue estimates decrease by 49%

Price target decreased by 7.1% to US$48.53

Recent updates

Independent Director notifies of intention to sell stock

Consensus revenue estimates fall by 49%

New major risk - Revenue size

Co-Founder notifies of intention to sell stock

Director notifies of intention to sell stock

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

New minor risk - Insider selling

Insider notifies of intention to sell stock

Consensus revenue estimates decrease by 14%

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Consensus revenue estimates decrease by 45%, EPS upgraded

First half 2024 earnings released: US$1.27 loss per share (vs US$0.53 profit in 1H 2023)

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Director notifies of intention to sell stock

Now 21% undervalued

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Consensus revenue estimates fall by 29%

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial

Denali Therapeutics Inc., Annual General Meeting, May 31, 2024

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Consensus revenue estimates decrease by 49%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Co-Founder notifies of intention to sell stock

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium

Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier (Bbb)-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium

Insufficient new directors

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Co-Founder recently sold US$340k worth of stock

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Co-Founder notifies of intention to sell stock

Price target decreased by 7.1% to US$48.53

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Consensus EPS estimates upgraded to US$1.01 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Denali Therapeutics Inc. Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Consensus revenue estimates increase by 279%

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 21%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

Consensus revenue estimates increase by 29%

Co-Founder notifies of intention to sell stock

Co-Founder exercised options and sold US$198k worth of stock

Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Consensus EPS estimates fall by 18%

Co-Founder recently sold US$105k worth of stock

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

Co-Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

Co-Founder notifies of intention to sell stock

Co-Founder recently sold US$144k worth of stock